Abstract
Human gliomas are highly invasive, and remain to be a major obstacle for any effective therapeutic remedy. Among many other factors, gliomas express elevated levels of matrix metalloproteinases (MMPs), which have been implicated to play an important role in tumor invasion as well as neovascularization. The tumor suppressor gene mutated in multiple advanced cancers/phosphatase and tensin homologue (MMAC/PTEN) has been shown to inhibit cell migration, spreading, and focal adhesion. In this study, we determined whether MMAC/PTEN inhibits tumor invasion by modulating MMP-2 activity. Our results showed that reintroduction of the MMAC/PTEN gene into human glioma U251 and U87 cells modified their phenotype and growth characteristics. The ability of MMAC/PTEN to induce anoikis in U251 cells was accompanied by a significant inhibition of in vitro invasion (70%). Expression of MMAC/PTEN in U251 and U87 cells inhibited MMP-2 enzymatic activity as determined by zymography. Furthermore, MMAC/PTEN expression strongly decreased MMP-2 mRNA levels, which correlated well with the inhibition of invasion capacity in these cells. Concomitant with MMP-2 expression and activity, MMP-2 promoter activity was also reduced in MMAC/PTEN expressing cells. Our observations suggest that MMAC/PTEN inhibits tumor cell invasion in part by regulating MMP-2 gene transcription and thereby its enzymatic activity. Further characterization of this regulation will facilitate the development of MMAC/PTEN based gene therapy for gliomas.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- MMAC/PTEN:
-
mutated in multiple advanced cancers/phosphatase and tensin homologue
- ECM:
-
extracellular matrix
- MMP:
-
matrix metalloproteinases
- TIMPs:
-
tissue inhibitors of metalloproteinases
- CM:
-
conditioned medium
- DMEM:
-
Dulbecco's modified Eagle's medium.
References
Agarwal C, Hembree JR, Rorke EA, Eckert RL . 1994 Cancer Res. 54: 943–949
Albelda SM . 1993 Lab. Invest. 68: 4–17
Albini A, Melchiori A, Santi L, Liotta LA, Brown PD, Stetler-Stevenson WG . 1991 J. Natl. Cancer Inst. 83: 775–779
Apodaca GT, Rutka K, Bouhana ME, Berens JR, Giblin ML, Rosenblum JH, Mckerrow M, Banda J . 1990 Cancer Res. 50: 2322–2329
Barillé SC, Akhoundi M, Collette MP, Mellerin MJ, Rapp JL, Harousseau R, Bataille M, Aminot M . 1997 Blood. 90: 1649–1655
Bjerkvig R, Laerum OD, Mella O . 1986 Cancer Res. 46: 407–409
Bian J, Sun Y . 1997 Mol. Cell. Biol. 17: 6330–6338
Cairns P, Okami K, Halachmi S, Halachm N, Esteller M, Herman JG, Jen J, Isaacs WB, Bova GS, Sidransky D . 1997 Cancer Res. 57: 4997–5000
Cheney IW, Johnson DE, Vaillancourt MT, Avanzini J, Morimoto A, Demers GW, Wills KN, Shabram PW, Bolen JB, Tavtigian SV, Brookstein R . 1999 Cancer Res. 58: 2331–2334
Chintala SK, Sawaya R, Gokaslan ZL, Rao JS . 1996 Cancer Lett. 103: 201–208
Chintala SK, Rao JK . 1996 Front Bioscience 1: 324–339
Cockett MI, Birch ML, Murphy G, Hart IR, Docherty AJ . 1994 Biochem. Soc. Trans. 22: 55–57
Davies B, Waxman J, Wasan H, Abel P, Williams G, Krausz T, Neal D, Thomas D, Hanby A, Balkwill F . 1993 Cancer Res. 22: 5365–5369
Davies MA, Lu Y, Sano T, Fang X, Tang P, LaPushin R, Koul D, Bookstein R, Stokoe D, Yung WK, Mills GB, Steck PA . 1998 Cancer Res. 58: 5285–5290
Deryugina EI, Luo GX, Reisfeld RA, Bourdon MA, Strongin A . 1997 Anticancer Res. 17: 3201–3210
Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP . 1998 Nat. Genet. 19: 348–355
Edwards DR, Beaudry PP, Laing TD, Kowal V, Leco KJ, Leco PA, Lim MS . 1996 Int. J. Obes. Relat. Metab. Disord. 20: Suppl 3 S9–S15
Fang J, Shing Y, Wiederschain D, Yan L, Butterfield C, Jackson G, Harper J, Tamvakopoulos G, Moses MA . 2000 Proc. Natl. Acad. Sci. USA 97: 3884–3889
Frisch SM, Francis H . 1994 J. Cell Biol. 124: 619–626
Furnari FB, Huang HJ, Cavenee WK . 1998 Cancer Res. 58: 5002–5008
Furnari FB, Lin H, Huang HJ, Cavenee WK . 1997 Proc. Natl. Acad. Sci. USA 94: 12479–12484
Guldberg P, Thor Straten P, Birck A, Ahrenkiel V, Kirkin AF, Zeuthen J . 1997 Cancer Res. 57: 3660–3663
Himelstein BP, Canete-Soler EJ, Bernhard DW, Dilks RJ, Muschel R . 1995 Invasion Metastasis. 14: 246–258
Kim H, Koh G . 2000 Biochem. Biophys. Res. Commun. 269: 401–405
Koul D, Yao Y, Abbruzzese JL, Yung WK, Reddy SA . 2001 J. Biol. Chem. 276: 11402–11408
Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigne S, Giovanell BC, Ittmann M, Tycko B, Hibshoosh H, Wigler M, Parsons R . 1997 Science. 275: 1943–1947
Li DM, Sun H . 1998 Proc. Natl. Acad. Sci. USA. 22: 15406–15411
Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z, Bose S, Call KM, Tsou HC, Peacock M, Eng C, Parsons R . 1997 Nat. Genet. 16: 64–67
Lu Y, Lin YZ, LaPushin R, Cuevas B, Fang X, Yu SX, Davies MA, Khan H, Furui T, Mao M, Zinner R, Hung MC, Steck P, Siminovitch K, Mills GB . 1999 Oncogene. 18: 7034–7045
Maehama T, Dixon JE . 1998 J. Biol. Chem. 273: 13375–13378
Maier D, Jones G, Li X, Schonthal AH, Gratzl O, Van Meir EG, Merlo A . 1999 Cancer Res. 21: 5479–5482
Marsh DJ, Dahia PL, Zheng Z, Liaw D, Parsons R, Gorlin RJ, Eng C . 1997 Nat. Genet. 16: 333–334
Meyers MP, Stolarov JP, Eng C, Li J, Wang SI, Wigler MH, Parson R, Tonks NK . 1997 Proc. Natl. Acad. Sci. USA 94: 9052–9057
Mignatti P, Rifkin DB . 1993 Physiol Rev. 73: 161–195
Mohanam S, Sawaya R, McCutcheon I, Ali-Osman F, Boyd D, Rao JS . 1993 Cancer Res. 53: 4143–4147
Morimoto AM, Berson AE, Fujii GH, Teng DH, Tavtigian SV, Bookstein R, Steck PA, Bolen JB . 1999 Oncogene 11: 1261–1266
Moscatelli D, Rifkin DB . 1988 Biochim. Biophys. Acta 948: 67–85
Moser TL, Young TN, Rodriguez GC, Pizzo SV, Bast Jr RC, Stack MS . 1994 Int. J. Cancer 56: 552–559
Nakajima M, Welch DR, Wynn DM, Tsuruo T, Nicolson GL . 1993 Cancer Res. 23: 5802–5807
Nakano AE, Tani K, Miyazaki Y, Yamamoto JI, Furuyama I . 1995 J. Neurosurg. 83: 298–307
Qin H, Moellinger JD, Wells A, Windsor LJ, Sun Y, Benveniste EN . 1998 J. Immunol. 12: 6664–6673
Rao JS, Steck PA, Tofilon P, Boyd D, Ali-Osman F, Stetler-Stevenson WG, Liotta LA, Sawaya R . 1994 J. Neurooncol. 18: 129–138
Rhei E, Kang L, Bogomolniy F, Federici MG, Borgen PI, Boyd J . 1997 Cancer Res. 57: 3657–3659
Rucklidge GJ, Edvardsen K, Bock E . 1994 Biochem. Soc. Trans. 22: 63–68
Sato H, Kida Y, Mai M, Endo Y, Sasaki T, Tanaka J, Seiki M . 1992 Oncogene 7: 77–83
Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Seiki M . 1994 Nature 370: 61–65
Seftor RE, Seftor EA, Stetler-Stevenson WG, Hendrix MJ . 1993 Cancer Res. 53: 3411–3415
Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, Ruland J, Penninger JM, Siderovski DP, Mak TW . 1998 Cell 95: 29–39
Steck PA, Perhouse MA, Jasser SA, Yung WKA, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DHF, Tavtigian SV . 1997 Nat. Genet. 15: 356–362
Stetler-Stevenson WG, Hewitt R, Corcoran M . 1996 Semin. Cancer Biol. 7: 147–154
Tamura M, Gu J, Matsumoto K, Aota S, Parsons R, Yamada KM . 1998 Science 280: 1614–1617
Tamura M, Gu J, Danen EH, Takino T, Miyamoto S, Yamada KM . 1999 J. Biol. Chem. 274: 20693–20703
Tashiro H, Blazes MS, Wu R, Cho KR, Bose S, Wang SI, Li J, Parsons R, Ellenson LH . 1997 Cancer Res. 57: 3935–3940
Tian XX, Pang JC, To SS, Ng HK . 1999 J. Neuropathol. Exp. Neurol. 58: 472–479
Uhm JH, Dooley NP, Villemure JG, Yong VW . 1997 Can. J. Neuro. Sci. 24: 3–15
Uhm JH, Dooley NP, Villemure JG, Yong VW . 1996 Clin. Exp. Metastasis 14: 421–433
Vassalli JD, Pepper MS . 1994 Nature 370: 14–15
Wang SI, Puc J, Li J, Bruce JN, Cairns P, Sidransky D, Parsons R . 1997 Cancer Res. 57: 4183–4186
Xuan JW, Tuck AB, Wilson SM, Chin Jl, Chambers AF . 1998 Anticancer Res. 18: 743–749
Yong VW, Krekoski CA, Forsyth PA, Bell R, Edwards DR . 1998 Trends Neurosci. 21: 75–80
Acknowledgements
This work was supported by grants RO1 CA 51148 to WKA Yung from the National Institute of Health, a grant from the Gilland Foundation to WKA Yung; and Cancer Center Core Grant, CA16672.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Koul, D., Parthasarathy, R., Shen, R. et al. Suppression of matrix metalloproteinase-2 gene expression and invasion in human glioma cells by MMAC/PTEN. Oncogene 20, 6669–6678 (2001). https://doi.org/10.1038/sj.onc.1204799
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204799
Keywords
This article is cited by
-
Repurposing FDA-approved drugs as inhibitors of therapy-induced invadopodia activity in glioblastoma cells
Molecular and Cellular Biochemistry (2023)
-
Integrative analysis of multiple types of genomic data using an accelerated failure time frailty model
Computational Statistics (2021)
-
Extracellular gamma-synuclein promotes tumor cell motility by activating β1 integrin-focal adhesion kinase signaling pathway and increasing matrix metalloproteinase-24, -2 protein secretion
Journal of Experimental & Clinical Cancer Research (2018)
-
Neuropilin-1 (NRP-1)/GIPC1 pathway mediates glioma progression
Tumor Biology (2016)
-
Differential SKIP expression in PTEN-deficient glioblastoma regulates cellular proliferation and migration
Oncogene (2015)